Skip to content

Clinical application of myasthenia gravis intelligent condition assessment and diagnosis system

Clinical application of myasthenia gravis intelligent condition assessment and diagnosis system

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300077300
Enrollment
Unknown
Registered
2023-11-03
Start date
2023-11-08
Completion date
Unknown
Last updated
2023-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myasthenia Gravis

Interventions

Sponsors

Beijing Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
10 Years to 80 Years

Inclusion criteria

Inclusion criteria: MG group: 1) Aged 10-80 years, according with the MG diagnostic criteria in the 2015 edition of the Chinese Expert Consensus on the Diagnosis and Treatment of MG; 2) Sign the informed consent before taking the scale and taking photos. Control group: 1) health without eye movement disorder and muscle weakness and muscle atrophy; 2) Sign the informed consent before taking the scale and taking photos.

Exclusion criteria

Exclusion criteria: 1) Patients with serious complications, such as heart dysfunction, respiratory dysfunction caused by severe lung disease, swallowing disorder caused by brain injury or other diseases, severe cervical spondylosis or lumbar spine disease; 2) There are other factors that may interfere with the evaluation, such as limited activity after thymus extraction, limb pain patients, etc.; 3) Can not understand the MG scale score so that the scoring process can not be completed.

Design outcomes

Primary

MeasureTime frame
Xu's absolute score and relative score;QMG score;

Secondary

MeasureTime frame
MG-ADL score;MG-QOL-15R score;EQ-5D-5L score;Myasthenia Gravis Composite,MGC;

Countries

China

Contacts

Public ContactYin Jian

Beijing Hospital

m13611177824@163.com+86 10 8513 3217

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026